With Cytometric Bead Assay, the Interleukin-10/HBV DNA Ratio Is an Early Predictor for Response to Interferon-α Treatment in Chronic Hepatitis B To cite this article:
Yan Taotao, He Yingli, Li Yuanyuan, Wang Jing, Chen Tianyan, Yang Yuan, Liu Jinfeng, Jin Li, Zhang Yu, Yi Ruitian, and Zhao Yingren. Journal of Interferon & Cytokine Research. October 2015, 35(10): 779-784. doi:10.1089/jir.2015.0004.
Published in Volume: 35 Issue 10: September 29, 2015
Online Ahead of Print: June 10, 2015
Author information
Taotao Yan,1,[url=]*[/url]
Yingli He,1,[url=]*[/url]
Yuanyuan Li,2,[url=]*[/url]
Jing Wang,1
Tianyan Chen,1
Yuan Yang,1
Jinfeng Liu,1
Li Jin,1
Yu Zhang,1
Ruitian Yi,1 and Yingren Zhao1
1Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China.
2Department of Infectious Diseases, Xi'an Children's Hospital, Xi'an, China.
*These authors contributed equally to this manuscript. Address correspondence to:
Dr. Yingren Zhao
Department of Infectious Diseases
First Affiliated Hospital
School of Medicine
Xi'an Jiaotong UniversityNo. 277 Yanta West Road
Xi'an 710061
China
E-mail: [email protected]
Received 3 January 2015
Accepted 5 April 2015
ABSTRACT
Both host immunity and hepatitis B virus (HBV) contribute to the therapeutic response to interferon (IFN)-α treatment in chronic hepatitis B (CHB) based on the immune modulation function to eliminate virus, while neither viral load nor cytokine alone could reflect the complex interaction between host immune response and virus. This study aimed at exploring a parameter of combined immunological and virological indexes to predict the response profile to IFN-α treatment in patients with CHB. Biochemical (alanine transaminase), virological (HBV DNA load, HBsAg, HBeAg), and immunological [IFN-γ, tumor necrosis factor (TNF), interleukin (IL)-2, IL-4, IL-6, and IL-10] indexes were dynamically monitored (at baseline, 2, 4, 8, 12, 24, 36, 48, and 72 weeks) in 41 patients who received a 48-week IFN-α treatment. First, we found that responders displayed an elevation in both Th1 and Th2 type cytokines from baseline to 4 weeks. What is more, the HBV DNA load at the baseline and IL-10 at 4 weeks showed significant differences between responders and nonresponders and were highly associated with the response to IFN-α treatment. More importantly, IL-10/HBV DNA was identified as a positive predictor for response to IFN-α treatment (odds ratio=5.785) by logistic regression analysis. We show here that the IL-10/HBV DNA ratio, a parameter of combined immunological and virological factors, can be useful in predicting the response to IFN-α treatment in CHB.
|